Tags : Outside

Dr. Reddy’s and GRA Collaborate with Fujifilm for Avigan (favipiravir)

Shots: Fujifilm to receive upfront, license fee along with royalties on sales of the therapy. Dr. Reddy’s and GRA to get the exclusive right to develop & commercialize Avigan globally (Ex- Japan). Additionally, Dr. Reddy’s would have exclusive rights for the therapy in India Fujifilm will provide pre/ clinical data of Avigan to Dr. Reddy’s […]Read More

Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma

Shots: Eisai to receive $110M upfront and $220M on marketing approval for tazemetostat in the US for certain indications and Royalty Pharma to get rights to receive royalties from Epizyme on sales outside of Japan In 2015, Epizyme and Eisai made amendment in their agreement for Tazemetostat candidate where Eisai will develop and commercialize in […]Read More

Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health

Shots: Leo Pharma to get exclusive rights to develop & commercialize brodalumab in Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia for the treatment of moderate-to-severe psoriasis The sub-licensing agreement complements the ongoing licensing agreement b/w Leo & AstraZeneca to develop & commercialize brodalumab in Europe. Bausch Health has the rights to commercialize brodalumab through […]Read More

Theramex Signs an Exclusive License Agreement with Therapeutics MD to

Shots: Therapeutics MD to receive $15.82M upfront, $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories Theramex to get exclusive commercialization rights for Bijuva and Imvexxy outside the US and is responsible for all regulatory and commercial activities in the licensed territories. Additionally, Therapeutics MD […]Read More